Leerink Partnrs Predicts Genmab A/S Q3 Earnings

Genmab A/S (NASDAQ:GMAB) – Equities researchers at Leerink Partnrs issued their Q3 2025 earnings per share estimates for Genmab A/S in a report issued on Thursday, February 13th. Leerink Partnrs analyst J. Chang anticipates that the company will post earnings of $0.43 per share for the quarter. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.25 per share. Leerink Partnrs also issued estimates for Genmab A/S’s FY2025 earnings at $1.59 EPS and FY2026 earnings at $1.99 EPS.

A number of other analysts also recently commented on GMAB. BMO Capital Markets restated an “outperform” rating and set a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research note on Thursday, January 23rd. Leerink Partners raised Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price objective on the stock in a research note on Thursday. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Finally, BNP Paribas raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th. Four research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $42.17.

Genmab A/S Trading Up 1.8 %

Shares of NASDAQ:GMAB opened at $21.30 on Monday. The firm has a market cap of $14.10 billion, a price-to-earnings ratio of 20.68, a PEG ratio of 0.54 and a beta of 0.96. The stock’s 50-day moving average price is $20.65 and its two-hundred day moving average price is $23.11. Genmab A/S has a 12-month low of $18.64 and a 12-month high of $31.88.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.29. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%.

Institutional Trading of Genmab A/S

A number of institutional investors and hedge funds have recently modified their holdings of the business. EverSource Wealth Advisors LLC boosted its holdings in shares of Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock valued at $26,000 after buying an additional 939 shares during the period. Lindbrook Capital LLC lifted its holdings in Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock worth $39,000 after acquiring an additional 950 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after purchasing an additional 1,051 shares during the last quarter. Barclays PLC grew its holdings in shares of Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company’s stock valued at $52,000 after purchasing an additional 2,285 shares during the last quarter. Finally, Cromwell Holdings LLC lifted its holdings in shares of Genmab A/S by 656.8% in the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock worth $60,000 after purchasing an additional 2,496 shares during the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.